Year: 2022

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announce that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’, it has today published the Information Note, as required by the Euronext Growth Market Rules Book…

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company is pleased to announce that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’ following the approval by Euronext of its request for listing. Admission is expected to take effect from 19 December 2019. This new listing does not…

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company’s share price and speculation concerning a…

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13–15 January 2020, at the Hilton, San Francisco Union Square. Dr Tim Franklin, Commercial Advisor to ImmuPharma, will be presenting to conference attendees on 14th January 2020…

TR1 – Notification of major interest in shareholdings Please click here

ImmuPharma and Avion Pharmaceuticals sign exclusive licence and development agreement and trademark agreement for Lupuzor™ with Avion to fund new international Phase III trial and commercialise in the US ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2019 (the “Period”). Key Highlights (including post Period review) Financials Stable financial performance over the Period – Cash balance of £2.3 million as at 30 June 2019 (31 December…

For further information click here

For full information click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.